Cover Image
Market Research Report
Product code
1002050

Global Opioid Induced Constipation Treatment Market, Size, Share, Opportunities and Forecast, 2020-2027

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Opioid Induced Constipation Treatment Market, Size, Share, Opportunities and Forecast, 2020-2027
Published: April 3, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

Global Opioid Induced Constipation Treatment Market is segmented By Drug Class (Mu-Opioid Receptor Antagonists (including PAMORAs) (Methylnaltrexone, Naloxegol, Naldemedine, Others), Chloride Channel Activators (Lubiprostone, Others), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Mode of administration (Oral, Parenteral), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Opioid-Induced Constipation Treatment Market is expected to grow at a CAGR of 4.1% during the forecasting period (2020-2027).

Opioid-induced constipation (OIC) is a type of secondary illness associated with prolonged use of opioids. Approximately 40%-80% of patients receiving opioid analgesics may experience OIC.

Global Opioid-Induced Constipation Treatment Market is estimated to reach USD 5 billion by 2026.

Industry Dynamics

The market is primarily driven by an expanding the base of OIC sufferers as a result of increased use of opioids in the treatment of chronic pain.

The global burden of chronic pain is significant and growing with over 1.5 billion people suffering from it. However, lack of awareness about opioid-induced constipation in patients is likely to limit the market growth.

Also, there is a vast unmet need in the market for highly-targeted, safe and efficient therapeutic options for OIC management.

Traditional first-line approaches to treating OIC such as laxatives have limited efficacy. OIC can be chronic and may be unresponsive to common laxative treatment regimens.

Market Segmentation

Opioid-Induced Constipation Treatment market report segments the market by drug class, by the method of administration, by distribution channel, and by region.

Based on drug class, the OIC treatment market is categorized into Mu- Opioid Receptor Antagonist, Locally Acting Chloride Channel Activator, Peripherally-Restricted Mu-opioid Receptor Antagonist, and Non-selective Opioid Antagonist.

Mu-opioid Receptor Antagonists segment is likely to overtake chloride channel activators by 2025 regarding market share and revenue generation due to its higher efficacy compared to other drugs.

Based on the mode of administration, the market is segmented into oral and parenteral.

Based on the distribution channel, the market is segmented into a drug store, independent pharmacies, and hospital pharmacies.

By Geography, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

North America dominates the market for Opioid-Induced Constipation Treatment owing to the high rate of opioid prescription as opioids remain the most commonly used major pain-relieving medications for chronic non cancer pain.

Key Segments Covered in the report

By Drug Class

Mu-Opioid Receptor Antagonist

Locally Acting Chloride Channel Activator

Peripherally-Restricted Mu-opioid Receptor Antagonist

Non-selective Opioid Antagonist

By Mode of Administration

Oral

bowel movements

Parenteral

abdominal pain

By Distribution Channel

Hospital Pharmacies

Independent Pharmacies

Drug stores

By Region

Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

North America (The USA, Canada, Mexico)

South America (Brazil, Argentina, Rest of South America)

Rest of the World

The report also profiles the following companies in Opioid-Induced Constipation Treatment market - GlaxoSmithKline, Inc., AstraZeneca plc, Inc., Pfizer, Inc., S.L.A. Pharma AG, AIKO Biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.

Reasons for purchasing this report?

Visualize the composition of Opioid-Induced Constipation Treatment market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of the Opioid-Induced Constipation Treatment market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for critical products of all major market players

Who can benefit from this report?

Equipment Suppliers/ Buyers

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

Table of Contents

Table of Contents

1. Opioid-Induced Constipation Treatment Market - Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 The scope of the Report

2. Opioid-Induced Constipation Treatment Market - Industry Trends

  • 2.1 Key Trends & Developments

3. Opioid-Induced Constipation Treatment Market - Market Outlook

  • 3.1 Market Drivers
    • 3.1.1 Expanding base of OIC sufferers due to increased use of opioids
  • 3.2 Market Restraints
    • 3.2.1 Lack of awareness about opioid-induced constipation in patients
  • 3.3 Threats and Opportunities

4. Opioid-Induced Constipation Treatment Market Forecast - Segmentation Analysis

  • 4.1 By Drug Class
    • 4.1.1 Mu-Opioid Receptor Antagonists (including PAMORAs)
      • 4.1.1.1 Methylnaltrexone
      • 4.1.1.2 Naloxegol
      • 4.1.1.3 Naldemedine
      • 4.1.1.4 Others
    • 4.1.2 Chloride Channel Activators
      • 4.1.2.1 Lubiprostone
      • 4.1.2.2 Others
    • 4.1.3 Others
  • 4.2 By Distribution Channel
    • 4.2.1 Hospital Pharmacies
    • 4.2.2 Retail Pharmacies
    • 4.2.3 Online Pharmacies
  • 4.3 By Mode of administration
    • 4.3.1 Oral
    • 4.3.2 Parenteral

5. Opioid-Induced Constipation Treatment Market - Regional, Country-level Analysis

  • 5.1. North America
    • 5.1.1. The USA
    • 5.1.2. Canada
    • 5.1.3. Mexico
  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. The UK
    • 5.2.4. Italy
    • 5.2.5. Spain
    • 5.2.6. Rest of Europe
  • 5.3. Asia Pacific
    • 5.3.1. China
    • 5.3.2. Japan
    • 5.3.3. India
    • 5.3.4. Australia
    • 5.3.5. Rest of Asia Pacific
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
    • 5.4.3. Rest of South America
  • 5.5 Rest of the World

6. Opioid-Induced Constipation Treatment Market - Competitive Trends

  • 6.1. Market Share Analysis
  • 6.2. Mergers and Acquisitions Analysis
  • 6.3. New Product Launches

7. Opioid-Induced Constipation Treatment Market - Company Profiles

  • 7.1 GlaxoSmithKline, Inc.
  • 7.2 AstraZeneca plc, Inc.
  • 7.3 Pfizer, Inc.
  • 7.4 L.A. Pharma AG
  • 7.5 AIKO Biotechnology
  • 7.6 Cubist Pharmaceuticals
  • 7.7 Salix Pharmaceuticals, Inc.
  • 7.8 Takeda Pharmaceutical Company Limited

8. Opioid-Induced Constipation Treatment Market - Appendix

  • 8.1 Sources
  • 8.2 List of Tables
  • 8.3 Expert Panel Validation
  • 8.4 Disclaimer
  • 8.5 Contact Us